今天太晚了，哪位兄弟有空帮翻译成中文吧
不过可惜还在动物实验期。。。
2010-8-16日的消息
http://www.thestreet.com/story/10836282/1/nanoviricides-reports-that-its-drug-candidates-demonstrated-significant-inhibition-of-herpes-virus-infection.html?cm_ven=GOOGLEFINanoViricides Reports That Its Drug Candidates Demonstrated Significant Inhibition Of Herpes Virus Infection
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.
More on Press Releases
Several of the anti-Herpes nanoviricides® demonstrated a dose-dependent maximal inhibition of Herpes virus infectivity in a cell culture model. Almost complete inhibition of the virus production was observed at clinically usable concentrations. These studies employed the H129 strain of herpes simplex virus type 1 (HSV-1). H129 is an encephalitic strain that closely resembles a clinical isolate; it is known to be more virulent than classic HSV-1 laboratory strains. The H129 strain will be used in subsequent animal testing of nanoviricides.
This anti-HSV program is designed for the development of an effective anti-herpes nanoviricide drug for the treatment of cold sores or genital herpes simplex virus infections. The Company plans to develop this drug as a skin cream or ointment formulation for external application.
The nanoviricides® mechanism of action is believed to mimic a natural host cell receptor by which the virus binds and infects cells; binding of a nanoviricide nanomicelle to the virus renders it non-infectious. A nanoviricide would thus stop the spread of the viral infection to new uninfected cells. This mechanism is different from that of currently available anti-Herpes drugs and therefore is expected to be complementary to that of the current drugs.
“These results extend the earlier results of our anti-Herpes nanoviricides® testing in different HSV-1 cell culture models at other laboratories,” said Randall Barton, PhD, Chief Scientific Officer of the Company, adding, “These studies will enable the selection of optimal anti-Herpes nanoviricides® for evaluation in animal models of Herpes virus infections.”
